VLA 2001
Alternative Names: VLA-2001Latest Information Update: 28 Mar 2023
At a glance
- Originator Valneva
- Developer National Institute for Health Research; Valneva
- Class Adjuvants; Attenuated vaccines; COVID-19 vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 13 Mar 2023 Valneva completes a phase III trial in COVID-2019 infections (In adolescents, In the elderly, Prevention, In adults) in United Kingdom (IM) (NCT04864561)
- 02 Mar 2023 Updated immunogenicity and safety data from a phase III trial in COVID-2019 infections (In adults, In the elderly, In adolescents, Prevention) released by Valneva
- 02 Mar 2023 Updated immunogenicity data from a phase III trial in COVID-2019 infections (Prevention) released by Valneva